Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment - Pharmacology & Pharmacy

PP > Vol.11 No.2, February 2020

Pharmacology & Pharmacy

Volume 11, Issue 2 (February 2020)

ISSN Print: 2157-9423 ISSN Online: 2157-9431

Google-based Impact Factor: 0.70 Citations h5-index & Ranking

Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment ()

HTML XML

Download as PDF (Size: 416KB) PP. 29-37

DOI: 10.4236/pp.2020.112004 525 Downloads 1,569 Views Citations

Author(s)

Ying Wang¹, Jingyi Zhao², Yinhui Yao^1*, Junhui Hu¹, Jiuli Hu¹, Xu Xiao¹, Yanwu Zhao^1*

Affiliation(s)

¹Department of Pharmacy, Affiliated Hospital of Chengde Medical College, Chengde, China.
²Department of Functional Center, Chengde Medical College, Chengde, China.

ABSTRACT

Dalbavancin is a novel semi-synthetic glycopeptide antibiotic. In this study, we aimed to optimize the dosage regimen of dalbavancin in patients with hepatic or renal impairment by Mote Carlo simulation. Pharmacokinetic parameters and microbiological data were collected about dalbavancin. 10,000 patients with renal or hepatic impairment analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). We found that all bacterial PTA and CFR were more than 90% for dalbavancin in patients with hepatic or renal impairment, except for Enterococcus faecium. There is no need to adjust the dosage regimen of dalbavancin in patients with hepatic or renal impairment.

KEYWORDS

Mote Carlo Simulation, Dalbavancin, Hepatic Impairment, Renal Impairment

Share and Cite:

Wang, Y. , Zhao, J. , Yao, Y. , Hu, J. , Hu, J. , Xiao, X. and Zhao, Y. (2020) Optimization of Dalbavancin in Patients with Hepatic or Renal Impairment. Pharmacology & Pharmacy, 11, 29-37. doi: 10.4236/pp.2020.112004.

Cited by

[1]	Long-Acting Lipoglycopeptide Antibiotics (Dalbavancin and Oritavancin) for the Treatment of Endotipsitis in a Patient With Cirrhosis: A Case Study
	Rivas, P Gupta… - Infectious Diseases in …, 2022

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies